cisapride   Click here for help

GtoPdb Ligand ID: 240

Synonyms: Prepulsid® | Propulsid®
Approved drug
cisapride is an approved drug (FDA (1993))
Compound class: Synthetic organic
Comment: Cisapride is an enantioneric mixture and we show the non-stereoisomeric structure here to represent the mixture. One stereoisomeric structure is shown by CHEMBL560739.
Cisapride must be used with caution due to reports of drug-induced arrhythmias and long QT syndrome. Although this drug was originally given marketing approval by the US FDA in 1993, all registered formulations have since been discontinued. In the EU (since 2002) conditions of use have been applied to active marketing authorisations for cisapride containing medicinal products.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 86.05
Molecular weight 465.18
XLogP 3.28
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N
Isomeric SMILES COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N
InChI InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)
InChI Key DCSUBABJRXZOMT-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Cisapride is used to treat motility related gastrointestinal disorders such as gastroesophageal reflux disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Cisapride is a serotonin 4 (5-HT4) receptor agonist which increases acetylcholine release, resulting in a combination of effects which culminate in accelerated gastric emptying and intestinal transit (eg increased tone and amplitude of gastric contractions, relaxation of the pyloric sphincter, increased duodenal and jejunal peristalsis).